Fate Therapeutics, Inc.
FATE
$0.9205
-$0.0458-4.74%
| Weiss Ratings | FATE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | FATE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | FATE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 2.29 | |||
| Price History | FATE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -8.86% | |||
| 30-Day Total Return | -27.52% | |||
| 60-Day Total Return | -51.04% | |||
| 90-Day Total Return | -66.65% | |||
| Year to Date Total Return | -48.58% | |||
| 1-Year Total Return | -86.92% | |||
| 2-Year Total Return | -83.44% | |||
| 3-Year Total Return | -97.56% | |||
| 5-Year Total Return | -95.99% | |||
| 52-Week High % Change | -87.45% | |||
| 52-Week Low % Change | 11.07% | |||
| Price | FATE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $7.70 | |||
| 52-Week Low Price | $0.87 | |||
| 52-Week Low Price (Date) | Mar 11, 2025 | |||
| 52-Week High Price (Date) | Mar 21, 2024 | |||
| Valuation | FATE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 110.74M | |||
| Enterprise Value | -83.06M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.65 | |||
| Earnings Per Share Growth | 0.92% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 8.35 | |||
| Price/Book (Q) | 0.35 | |||
| Enterprise Value/Revenue (TTM) | -6.09 | |||
| Price | $0.92 | |||
| Enterprise Value/EBITDA (TTM) | 0.47 | |||
| Enterprise Value/EBIT | 0.42 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | FATE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 117.79M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | FATE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 858 875 1800 | |||
| Address | 12278 Scripps Summit Drive San Diego, CA 92131 | |||
| Website | www.fatetherapeutics.com | |||
| Country | United States | |||
| Year Founded | 2007 | |||
| Profitability | FATE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -1,434.51% | |||
| Profit Margin | -1,366.45% | |||
| Management Effectiveness | FATE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -25.81% | |||
| Return on Equity | -- | |||
| Income Statement | FATE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 13.63M | |||
| Total Revenue (TTM) | 13.63M | |||
| Revenue Per Share | $0.12 | |||
| Gross Profit (TTM) | -104.90M | |||
| EBITDA (TTM) | -176.58M | |||
| EBIT (TTM) | -195.54M | |||
| Net Income (TTM) | -186.26M | |||
| Net Income Avl. to Common (TTM) | -186.26M | |||
| Total Revenue Growth (Q YOY) | 10.98% | |||
| Earnings Growth (Q YOY) | -18.20% | |||
| EPS Diluted (TTM) | -1.65 | |||
| EPS Diluted Growth (Q YOY) | 1.05% | |||
| Balance Sheet | FATE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 279.07M | |||
| Cash Per Share (Q) | $2.37 | |||
| Total Current Assets (Q) | 291.91M | |||
| Total Preferred Equity (Q) | 0.00 | |||
| Total Equity (Q) | 318.73M | |||
| Current Ratio (Q) | 7.578 | |||
| Book Value Per Share (Q) | $2.80 | |||
| Total Assets (Q) | 440.69M | |||
| Total Current Liabilities (Q) | 38.52M | |||
| Total Debt (Q) | 85.27M | |||
| Total Liabilities (Q) | 121.97M | |||
| Total Common Equity (Q) | 318.72M | |||
| Cash Flow | FATE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 12.22M | |||
| Cash from Financing (TTM) | 99.89M | |||
| Net Change in Cash (TTM) | -10.76M | |||
| Levered Free Cash Flow (TTM) | -60.77M | |||
| Cash from Operations (TTM) | -122.87M | |||
